174 related articles for article (PubMed ID: 20739765)
1. Statins: cost analysis in Indian scenario from eight major clinical trials.
Sanmukhani J; Shah V
J Postgrad Med; 2010; 56(3):196-200. PubMed ID: 20739765
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin: its clinical role in cerebrovascular prevention.
Gaspardone A; Arca M
Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.
Hay JW; Yu WM; Ashraf T
Pharmacoeconomics; 1999 Jan; 15(1):47-74. PubMed ID: 10345158
[TBL] [Abstract][Full Text] [Related]
5. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
6. Beyond lipid lowering: the role of statins in vascular protection.
Liao JK
Int J Cardiol; 2002 Nov; 86(1):5-18. PubMed ID: 12243846
[TBL] [Abstract][Full Text] [Related]
7. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting.
Gotto AM; Grundy SM
Circulation; 1999 Mar; 99(8):E1-7. PubMed ID: 10051310
[TBL] [Abstract][Full Text] [Related]
8. [Statins in primary prevention of coronary heart disease].
Paulweber B
Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
van Hout BA; Simoons ML
Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
[TBL] [Abstract][Full Text] [Related]
10. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting.
Natarajan P; Young R; Stitziel NO; Padmanabhan S; Baber U; Mehran R; Sartori S; Fuster V; Reilly DF; Butterworth A; Rader DJ; Ford I; Sattar N; Kathiresan S
Circulation; 2017 May; 135(22):2091-2101. PubMed ID: 28223407
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
Plosker GL; Lyseng-Williamson KA
Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
Pickin DM; McCabe CJ; Ramsay LE; Payne N; Haq IU; Yeo WW; Jackson PR
Heart; 1999 Sep; 82(3):325-32. PubMed ID: 10455083
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):29-36. PubMed ID: 15703503
[TBL] [Abstract][Full Text] [Related]
14. The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women.
Seed M
Atheroscler Suppl; 2002 May; 3(1):53-63. PubMed ID: 12044587
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Arca M
Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of statins: their role in secondary prevention.
Tonkin AM
Atheroscler Suppl; 2001 Feb; 2(1):21-5. PubMed ID: 11286152
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
Lim SS; Vos T; Peeters A; Liew D; McNeil JJ
Med J Aust; 2001 Nov; 175(9):459-64. PubMed ID: 11758073
[TBL] [Abstract][Full Text] [Related]
18. Protecting the heart: a practical review of the statin studies.
Ong HT
MedGenMed; 2002 Dec; 4(4):1. PubMed ID: 12817199
[TBL] [Abstract][Full Text] [Related]
19. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
Sever PS
Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
[TBL] [Abstract][Full Text] [Related]
20. Lipid-lowering for prevention of coronary heart disease: what policy now?
Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
